Autophagy-regulated strategies in pre-clinical studies of inflammatory bowel disease
10.16438/j.0513-4870.2022-0836
- VernacularTitle:自噬调节策略在炎症性肠病临床前研究中的进展
- Author:
Wen-sheng YANG
1
;
Wei WU
1
;
Jing-lin WANG
2
;
Guang-fei WANG
1
;
Zhi-ping LI
1
Author Information
1. Department of Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China
2. Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
- Publication Type:Research Article
- Keywords:
inflammatory bowel disease;
autophagy;
intestinal epithelial cell;
macrophage;
intestinal barrier
- From:
Acta Pharmaceutica Sinica
2023;58(1):1-8
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD) is a group of chronic idiopathic colorectal inflammatory diseases with a progressive and unpredictable course, including ulcerative colitis (UC) and Crohn's disease (CD). Abnormal intestinal inflammation and immune response contribute to the pathogenesis of IBD. Autophagy as an essential catabolic process in cells, has been demonstrated to have associations with a variety of inflammatory diseases including IBD. Here, we review the relationship between autophagy dysfunction and the process of IBD. The progress of several autophagy regulators for intestinal epithelial cells and macrophages is highlighted (inflammasome inhibitors, intestinal flora regulators, and other signal regulators) in the current studies on IBD.
